Last reviewed · How we verify
Adjuvant: Montonide isa 51 VG
At a glance
| Generic name | Adjuvant: Montonide isa 51 VG |
|---|---|
| Sponsor | BiondVax Pharmaceuticals ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvant: Montonide isa 51 VG CI brief — competitive landscape report
- Adjuvant: Montonide isa 51 VG updates RSS · CI watch RSS
- BiondVax Pharmaceuticals ltd. portfolio CI